NYSE:HIMSHealthcare
Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration
In late March 2026, Hims & Hers Health announced a renewed collaboration with Novo Nordisk, adding a broad range of FDA-approved GLP-1 medications, including Wegovy weight loss pills and injections, plus Ozempic for Type 2 diabetes, to its telehealth platform with memberships starting at US$39 for the first month and medication prices from US$149 a month.
The partnership deepens Hims & Hers’ push into medically supervised weight management by pairing branded GLP-1 access with ongoing virtual...